• Publications
  • Influence
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
TLDR
The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
The landscape of somatic copy-number alteration across human cancers
TLDR
It is demonstrated that cancer cells containing amplifications surrounding the MCL1 and BCL2L1 anti-apoptotic genes depend on the expression of these genes for survival, and a large majority of SCNAs identified in individual cancer types are present in several cancer types.
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
TLDR
The data suggest that feedback down-regulation of receptor tyrosine kinase signaling is a frequent event in tumor cells with constitutive mTOR activation, and reversal of this feedback loop by rapamycin may attenuate its therapeutic effects, whereas combination therapy that ablates mTOR function and prevents Akt activation may have improved antitumor activity.
Systematic identification of genomic markers of drug sensitivity in cancer cells
TLDR
It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
TLDR
One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.
Trastuzumab emtansine for HER2-positive advanced breast cancer.
TLDR
T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
TLDR
The association between pathological complete response and long-term outcomes was strongest in patients with triple-negative breast cancer, and the prognostic value is greatest in aggressive tumour subtypes.
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.
TLDR
MAPK activation as a consequence of mTORC1 inhibition is identified and the potential of a combined therapeutic approach with m TORC1 and MAPK inhibitors, currently employed as single agents in the clinic, for the treatment of human cancers is underscore.
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
TLDR
Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromat enzyme inhibitors.
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
TLDR
A role for EMT in the blood-borne dissemination of human breast cancer is supported as both single cells and multicellular clusters, expressing known EMT regulators, including transforming growth factor (TGF)–β pathway components and the FOXC1 transcription factor.
...
1
2
3
4
5
...